Faculty of Medicine, Department of General Surgery 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania.
IV Department of Surgery, Emergency University Hospital, Bucharest, Romania.
In Vivo. 2022 Jan-Feb;36(1):40-48. doi: 10.21873/invivo.12674.
Aromatase inhibitor therapy is currently the preferred choice in postmenopausal women with estrogen receptor positive breast cancer. This article reviews the ocular side effects of treatment with aromatase inhibitors (AIs) in patients with breast cancer.
A comprehensive search was performed on PubMed, Web of Science and Google scholar.
After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema.
Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment.
芳香酶抑制剂治疗目前是绝经后雌激素受体阳性乳腺癌患者的首选。本文综述了乳腺癌患者使用芳香酶抑制剂（AIs）治疗的眼部副作用。
在 PubMed、Web of Science 和 Google Scholar 上进行了全面检索。
去除重复项后，共确定了 14 项临床研究和 5 项病例报告，这些研究报告发表于 2008 年至 2021 年期间。AIs 治疗最常导致轻微至中度干眼症状。也有报道称在 AI 治疗期间出现“新发”干燥综合征。视网膜和视神经副作用从轻度、亚临床解剖和功能损害到严重视力下降不等，原因是半中央视网膜动脉闭塞、双侧视神经炎或葡萄膜炎伴双侧黄斑水肿。
在 AI 治疗期间遇到的视力障碍可能被低估了。眼科筛查对于早期发现和适当治疗很重要。
Zotero 插件